- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 16 - Factors Hindering Care for SLE Patients
Despite the number of drugs currently in the pipeline for the treatment of systemic lupus erythematosus (SLE), the panelists raise concerns about unaddressed factors that may continue to impede a clinician’s decision to recommend a treatment option to a patient.
Michelle Petri, MD, MPH, explains that newly-approved therapy options still lack personalized biomarkers and do not provide important long-term outcomes data that help professionals make decisions about treatment for patients with SLE.
Patrick F. Fogarty, MD, further explains that when defining the value of medical therapy, an economic consideration continues to stand in the way of treatment recommendations.
Without addressing these issues, Dr Petri and Dr Fogarty agree that when selecting appropriate therapy for a patient, and when considering the costs associated with a treatment option, it is important to individualize therapy for patients with SLE.
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
